MindBio Therapeutics Corp. (CSE:MBIO)

Canada flag Canada · Delayed Price · Currency is CAD
0.8000
-0.2000 (-20.00%)
At close: Feb 4, 2026
Market Cap3.84M -3.9%
Revenue (ttm)n/a
Net Income-3.66M
EPS-5.55
Shares Out4.80M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,887
Average Volume17,030
Open1.0000
Previous Close1.0000
Day's Range0.8000 - 1.0000
52-Week Range0.5000 - 10.0000
Beta-0.86
RSI37.84
Earnings DateOct 29, 2025

About MindBio Therapeutics

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for de... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol MBIO
Full Company Profile

Financial Performance

Financial numbers in AUD Financial Statements